Treatment of systemic sclerosis: potential role for stem cell transplantation.

Document Type


Publication Date



This article has been peer reviewed. It was published in: Stem Cells Cloning.
2009 January; 2: 1–9.
The published version is available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3781687/.

Copyright © 2009 Xiong and Derk, publisher and licensee Dove Medical Press Ltd.


Hematopoietic stem cell transplantation may "reset" the immune reconstitution and induce self tolerance of autoreactive lymphocytes, and has been explored in the treatments for systemic sclerosis. Phase I/II trials have shown a satisfactory risk benefit ratio. The true benefit will be identified by two ongoing prospective, randomized phase III trials. Multipotent mesenchymal stromal cells (MSCs) possess antiproliferative, anti-inflammatory, and immunosuppressive properties. The use of MSCs has showed successful responses in patients with severe steroid-resistant acute graft versus host disease in phase II trials, and may be a potentially promising option for patients with systemic sclerosis.